Details of the various clinical trials and peer reviewed publications are available below. The US Federal Regulations restricts the display of certain non-US clinical data. Please declare your home country by selecting the appropriate tab below.


Harris et al., Oncology Letters 20: 17, 2020

This publication presents a sub-analysis of data collected during the IMPROVE-COLPO study, looking specifically at colposcopy patients that had been referred with ASC-US cytology. The IMPROVE-COLPO study was designed to assess the detection of women with high-grade cervical lesions when using the DYSIS digital colposcope with dynamic spectral imaging, in routine colposcopy across a wide range of US community-based clinics. Retrospective cases that had colposcopy with standard methods were used as controls for comparisons.


To assess the detection of women with precancerous lesions of the cervix and compare outcomes of conventional colposcopy to DYSIS digital colposcopy.


This analysis included women with an ASC-US cytology from screening (either with a HPV+ co-test, or persistent) and assessed the percentage of women found with CIN3+, the number of biopsied women and the numbers of biopsies.


The results from 1,226 women that had DYSIS colposcopy were compared to the results from 1,353 women that had had standard colposcopy. Although the number of women undergoing biopsy was similar across the two arms, and the number of biopsies increased only by <20% for those having a DYSIS colposcopy, the number of patients detected with histologically-confirmed CIN3+ increased by >70% when DYSIS was used for colposcopy.


Although ASC-US is a low-risk population, it still accounts for about a third of colposcopy referrals. It is therefore important to maximize detection of severe precancerous disease. This analysis suggests that the use of DYSIS with the adjunctive DSI mapping can assist clinicians to increase detection significantly without a significant negative impact on patients.


This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0]: